BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35805054)

  • 1. Impact of
    Felice MS; Rubio PL; Digiorge J; Barreda Frank M; Martínez CS; Guitter MR; Sajaroff EO; Sánchez La Rosa CG; Pennella CL; Peruzzo LB; Deu MA; Alfaro EM; Guardia MC; Gutierrez G; Fernández Barbieri MA; Recondo E; Vides Herrera MS; Livio V; Arnaiz C; Romero C; Alonso CN; Rossi JG;
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Garcia-Solorio J; Núñez-Enriquez JC; Jiménez-Olivares M; Flores-Lujano J; Flores-Espino F; Molina-Garay C; Cervera A; Casique-Aguirre D; Peñaloza-Gonzalez JG; Baños-Lara MDR; García-Soto Á; Galván-Díaz CA; Olaya-Vargas A; Aguilar HF; Mata-Rocha M; Garrido-Hernández MÁ; Solís-Poblano JC; Luna-Silva NC; Cano-Cuapio LS; Aristil-Chery PM; Herrera-Quezada F; Carrillo-Sanchez K; Muñoz-Rivas A; Flores-Lagunes LL; Mendoza-Caamal EC; Villegas-Torres BE; González-Osnaya V; Jiménez-Hernández E; Torres-Nava JR; Martín-Trejo JA; Gutiérrez-Rivera ML; Espinosa-Elizondo RM; Merino-Pasaye LE; Pérez-Saldívar ML; Jiménez-Morales S; Curiel-Quesada E; Rosas-Vargas H; Mejía-Arangure JM; Alaez-Verson C
    Front Oncol; 2024; 14():1337954. PubMed ID: 38634053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of IKZF1
    Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience.
    Crepinsek K; Marinsek G; Kavcic M; Prelog T; Kitanovski L; Jazbec J; Debeljak M
    Radiol Oncol; 2021 Dec; 56(1):92-101. PubMed ID: 34957727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols.
    Ampatzidou M; Papadhimitriou SI; Paisiou A; Paterakis G; Tzanoudaki M; Papadakis V; Florentin L; Polychronopoulou S
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Tang B; Cai Z; Wang Z; Lin D; He X; Li Q; Liang X; Huang K; Zhou X; Lin R; Xu N; Fan Z; Huang F; Sun J; Liu X; Liu Q; Zhou H
    Bone Marrow Transplant; 2022 Dec; 57(12):1751-1757. PubMed ID: 36056210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
    Palmi C; Bresolin S; Junk S; Fazio G; Silvestri D; Zaliova M; Oikonomou A; Scharov K; Stanulla M; Moericke A; Zimmermann M; Schrappe M; Buldini B; Bhatia S; Borkhardt A; Saitta C; Galbiati M; Bardini M; Lo Nigro L; Conter V; Valsecchi MG; Biondi A; Te Kronnie G; Cario G; Cazzaniga G
    Hemasphere; 2023 Jun; 7(6):e892. PubMed ID: 37304931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on
    Hrabovsky S; Vrzalova Z; Stika J; Jelinkova H; Jarosova M; Navrkalova V; Martenek J; Folber F; Salek C; Horacek JM; Pospisilova S; Mayer J; Doubek M
    Acta Oncol; 2021 Jun; 60(6):760-770. PubMed ID: 33750258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia.
    Maciel ALT; Barbosa TDC; Blunck CB; Wolch K; Machado AAL; da Costa ES; Bergier LL; Schramm MT; Ikoma-Coltutato MRV; Lins MM; Aguiar TF; Mansur MB; Emerenciano M
    Transl Oncol; 2022 Jan; 15(1):101291. PubMed ID: 34826720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
    Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
    Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
    Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Gupta SK; Bakhshi S; Kamal VK; Gupta R; Sharma P; Pushpam D; Sahoo RK; Sharma A
    Leuk Res; 2021 Dec; 111():106683. PubMed ID: 34371436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
    Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
    J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.
    Yamashita Y; Shimada A; Yamada T; Yamaji K; Hori T; Tsurusawa M; Watanabe A; Kikuta A; Asami K; Saito AM; Horibe K
    Pediatr Blood Cancer; 2013 Oct; 60(10):1587-92. PubMed ID: 23804397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
    Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
    Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.